

## Targeting MET in advanced NSCLC care: A multidisciplinary perspective

### Chair

**Enriqueta Felip, MD, PhD**, Vall d'Hebron University Hospital, Barcelona, Spain

### Faculty

**Umberto Malapelle, PhD**, University of Naples Federico II, Naples, Italy

**Release date: November 28, 2022**

**Estimated time to completion: 1.0 hour**

### Activity description

This educational activity consists of two EXPRESS expert presentations and an expert roundtable discussion, which will be submitted for accreditation.

During the EXPRESS expert presentations, the speakers will:

- Highlight their role in a patient-centered multidisciplinary team for the treatment of advanced NSCLC
- Illustrate the clinical value of MET alterations
- Examine current and upcoming treatment options for patients with MET alterations
- Showcase advanced molecular techniques for the identification and assessment of MET alterations
- Discuss monitoring and management of paraneoplastic syndromes, side effects of MET TKIs, and patient communication and expectation management

The roundtable discussion focuses on the implementation of a multidisciplinary team care plan and addresses coordination and communication strategies as well as practical insights for individualized treatment plans using targeted therapies.

### Target audience

This activity is intended for oncologists, pulmonologists, pathologists, and other healthcare professionals involved in the diagnosis, treatment, and management of NSCLC patients in Europe.

### Educational objectives

After completing this activity, the participant should be better able to:

- **Explain** the roles and responsibilities of different specialists within the MDT care team for advanced NSCLC
- **Integrate** advanced molecular diagnostic techniques to assess MET alterations in different clinical stages of the management of NSCLC
- **Develop** personalized treatment strategies, including the use of targeted therapies such as MET TKIs based on clinical evidence on their efficacy and safety, and also manage treatment-related side effects
- **Implement** patient-centered MDT care plans in clinical practice, making use of optimal communication and coordination techniques

**CPD accreditation**

This educational activity is CPD (Continuing Professional Development) accredited. More information regarding CPD credits can be found here: [CPD credits](#)

**Method of participation and request for credit**

There are no fees for participating in this activity.

To claim CPD credit, participants must complete the following procedures:

1. Read the educational objectives, accreditation information, and faculty disclosures
2. Complete the webcast and two EXPRESS expert presentations
3. Take the post-activity test and complete the evaluation
4. Indicate the number of credits earned and add these to [myCPD Portal](#)

**Disclosure of conflicts of interest**

<b>Faculty</b>	<b>Relationship identified with:</b>
Enriqueta Felip	<p>Receipt of grants/research supports: Fundación Merck Salud; grant for oncology innovation and Merck, Healthcare KGaA.</p> <p>Receipt of honoraria or consultation fees: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffman-LaRoche, Glaxo Smith Kline, Ipsen, Janssen, Medical Trends, Medscape, Merck KGaA, Merck Sharp &amp; Dohme, Novartis, PeerVoice, Peptomyc, Pfizer, Sanofi, Springer, Takeda, Touchtime.</p> <p>Other support: Grifols (independent member of the board).</p>
Umberto Malapelle	<p>Receipt of honoraria or consultation fees: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Diaceutics, Eli Lilly, Janssen, Merck, Merck Sharp &amp; Dohme, Roche, Thermo Fisher.</p> <p>Participation in a company-sponsored speaker's bureau: Amgen, AstraZeneca, Biocartis, Boehringer Ingelheim, Bristol Myers Squibb, Merck, Merck Sharp &amp; Dohme, Roche, Thermo Fisher.</p> <p>Spouse/partner: Roche.</p>

---

### Planners and managers

The Ology Medical Education planners and managers have nothing to disclose.

### Provider information

Provided by Ology Medical Education.



### Financial support

This activity is supported by an independent educational grant from Merck Serono S.p.A., Rome, Italy.

### Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

### Contact information for questions about the activity

[info@ologyeducation.org](mailto:info@ologyeducation.org), [www.ologyeducation.org](http://www.ologyeducation.org)

### System requirements

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

**Policy on Privacy and Confidentiality**

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

**Media**

Internet